The first experience of denosumab therapy on patients with Ehlers–Danlos syndrome and osteoporosis: detailed observation of two patients

References

• Malfait F, Francomano C, Byers P, et al. The 2017 international classification of the Ehlers–Danlos syndromes. Am J Med Genet C Semin Med Genet. 2017;175(1):8–26.
   PubMed Web of Science ®Google Scholar
• Colombi M, Dordoni C, Chiarelli N, et al. Differential diagnosis and diagnostic flow chart of joint hypermobility syndrome/Ehlers–Danlos syndrome hypermobility type compared to other heritable connective tissue disorders. Am J Med Genet C Semin Med Genet. 2015;169C(1):6–22.
   PubMedGoogle Scholar
• Demmler JC, Atkinson MD, Reinhold EJ, et al. Diagnosed prevalence of Ehlers–Danlos syndrome and hypermobility spectrum disorder in Wales, UK: a national electronic cohort study and case-control comparison. BMJ Open. 2019;9(11):e031365.
   PubMed Web of Science ®Google Scholar
• Eller-Vainicher C, Bassotti A, Imeraj A, et al. Bone involvement in adult patients affected with Ehlers–Danlos syndrome. Osteoporos Int. 2016;27(8):2525–2531.
   Web of Science ®Google Scholar
• Deodhar AA, Woolf AD. Ehlers Danlos syndrome and osteoporosis. Ann Rheum Dis. 1994;53(12):841–842.
   Web of Science ®Google Scholar
• Dolan AL, Arden NK, Grahame R, et al. Assessment of bone in Ehlers Danlos syndrome by ultrasound and densitometry. Ann Rheum Dis. 1998;57(10):630–633.
   PubMed Web of Science ®Google Scholar
• Ayoub S, Ghali N, Angwin C, et al. Clinical features, molecular results, and management of 12 individuals with the rare arthrochalasia Ehlers–Danlos syndrome. Am J Med Genet. 2020;182(5):994–1007.
   Web of Science ®Google Scholar
• Formenti AM, Doga M, Frara S, et al. Skeletal fragility: an emerging complication of Ehlers–Danlos syndrome. Endocrine. 2019;63(2):225–230.
   Web of Science ®Google Scholar
• Uehara M, Nakamura Y, Takahashi J, et al. Efficacy of denosumab for osteoporosis in three female patients with osteogenesis imperfecta. Tohoku J Exp Med. 2017;242(2):115–120.
   Web of Science ®Google Scholar
• Uehara M, Nakamura Y, Takahashi J, et al. Efficacy of denosumab therapy for a 21-year-old woman with Prader-Willi syndrome, osteoporosis and history of fractures: a case report. Ther Clin Risk Manag. 2019;15:303–307.
   PubMed Web of Science ®Google Scholar
• Coelho PC, Santos RA, Gomes JA. Osteoporosis and Ehlers–Danlos syndrome. Ann Rheum Dis. 1994;53(3):212–213.
   Web of Science ®Google Scholar
• Carbone L, Tylavsky FA, Bush AJ, et al. Bone density in Ehlers–Danlos syndrome. Osteoporos Int. 2000;11(5):388–392.
   Web of Science ®Google Scholar
• Theodorou SJ, Theodorou DJ, Kakitsubata Y, et al. Low bone mass in Ehlers–Danlos syndrome. Intern Med. 2012;51(22):3225–3226.
   Web of Science ®Google Scholar
• Mazziotti G, Dordoni C, Doga M, et al. High prevalence of radiological vertebral fractures in adult patients with Ehlers–Danlos syndrome. Bone. 2016;84:88–92.
   PubMed Web of Science ®Google Scholar
• Diédhiou D, Cuny T, Sarr A, et al. Efficacy and safety of denosumab for the treatment of osteoporosis: a systematic review. Ann Endocrinol (Paris). 2015;76(6):650–657.
   PubMed Web of Science ®Google Scholar
• Kumaki D, Nakamura Y, Suzuki T, et al. Efficacy of denosumab for osstehoporosis in two patients with adult-onset Still’s disease denosumab efficacy in osteoporotic Still’s disease patients. JCM. 2018;7(4):63.
   Google Scholar
• Uehara M, Nakamura Y, Takahashi J, et al. Efficacy of denosumab therapy for neurofibromatosis type I with osteoporosis and history of fractures: a case report. Mod Rheumatol Case Reports. 2018;2(1):92–96.
   Google Scholar
• Isobe F, Nakamura Y, Suzuki T, et al. Effects of denosumab on osteoporosis in three cases with anorexia nervosa and a review of the literature. Mod Rheumatol Case Reports. 2018;2(1):104–106.
   Google Scholar
• Kamimura M, Taguchi A, Nakamura Y, et al. Pretreatment of daily teriparatide enhances the increase of bone mineral density in cortical bones by denosumab therapy. Ther Clin Risk Manag. 2018;14:637–642.
   Web of Science ®Google Scholar
• Suzuki T, Nakamura Y, Kamimura M, et al. Denosumab significantly improves lumbar spine bone mineral density more in treatment-naïve than in long-term bisphosphonate-treated patients. Bone Rep. 2018;8:110–114.
   Google Scholar
• Uehara M, Nakamura Y, Suzuki T, et al. Efficacy of denosumab therapy after alendronate treatment for a 66-year-old woman with Camurati–Engelmann disease and osteoporosis: a case report. Mod Rheumatol Case Rep. 2020;4(1):131–134.
   PubMedGoogle Scholar
• Hajime M, Okada Y, Mori H, et al. A case of teriparatide-induced severe hypophosphatemia and hypercalcemia. J Bone Miner Metab. 2014;32(5):601–604.
   Web of Science ®Google Scholar
• Suzuki T, Nakamura Y, Kato H. Significant improvement of bone mineral density by denosumab without bisphosphonate pre-treatment in glucocorticoid-induced osteoporosis. Mod Rheumatol. 2018;28(5):885–889.
   PubMed Web of Science ®Google Scholar
• Nakamura Y, Suzuki T, Kamimura M, et al. Vitamin D and calcium are required at the time of denosumab administration during osteoporosis treatment. Bone Res. 2017;5(1):17021.
   PubMedGoogle Scholar
• Nakamura Y, Suzuki T, Kato H. Serum bone alkaline phosphatase is a useful marker to evaluate lumbar bone mineral density in Japanese postmenopausal osteoporotic women during denosumab treatment. TCRM. 2017;13:1343–1348.
   Google Scholar
• Austin M, Yang YC, Vittinghoff E, for the FREEDOM Trial, et al. Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fractures. J Bone Miner Res. 2012;27(3):687–693.
   PubMed Web of Science ®Google Scholar